\
&
Contact us
Culture and society EIT New European Bauhaus
EIT Culture & Creativity has opened its first funding calls as an implementing partner of the New European Bauhaus (NEB) Academy, the learning and innovation infrastructure of the NEB. These two calls offer a total of €6 million to support circular fashion and skills development for the transformation of Europe’s lived environme... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.